CD8A and neoplasm: The expansion of EDMCs was positively associated with intra-tumor PD-L1 expression, T cell exhaustion and immune tolerance in TME, which significantly inhibited antitumor immune responses of CD8+ T cells and greatly reduced the efficacy of immune checkpoint inhibitors, thus providing valuable prognostic biomarkers and a new therapeutic goal for clinical ICI treatment.